The a3 adenosine receptor: History and perspectives

Pharmacological Reviews

Volumn 67, Issue 1, 2015, Pages 74-102

  Borea, Pier Andrea ^a   Varani, Katia ^a   Vincenzi, Fabrizio ^a   Baraldi, Pier Giovanni ^a   Tabrizi, Mojgan Aghazadeh ^a   Merighi, Stefania ^a   Gessi, Stefania ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ADENOSINE A3 RECEPTOR; ADENOSINE A3 RECEPTOR AGONIST; ADENOSINE A3 RECEPTOR ANTAGONIST; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; LIGAND;

ANIMAL; DRUG DESIGN; DRUG EFFECTS; HISTORY; HUMAN; METABOLISM; MOLECULARLY TARGETED THERAPY; SIGNAL TRANSDUCTION;

ADENOSINE; ADENOSINE A3 RECEPTOR AGONISTS; ADENOSINE A3 RECEPTOR ANTAGONISTS; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; HISTORY, 20TH CENTURY; HUMANS; LIGANDS; MOLECULAR TARGETED THERAPY; RECEPTOR, ADENOSINE A3; SIGNAL TRANSDUCTION;

EID: 84916195581     PISSN: 00316997     EISSN: 15210081     Source Type: Journal    
DOI: 10.1124/pr.113.008540     Document Type: Article

References (373)

1. Abbracchio MP, Brambilla R, Ceruti S, Kim HO, von Lubitz DK, Jacobson KA, and Cattabeni F (1995) G protein-dependent activation of phospholipase C by adenosine A3 receptors in rat brain. Mol Pharmacol 48:1038–1045.
2. Abbracchio MP, Camurri A, Ceruti S, Cattabeni F, Falzano L, Giammarioli AM, Jacobson KA, Trincavelli L, Martini C, and Malorni W, et al. (2001) The A3 adenosine receptor induces cytoskeleton rearrangement in human astrocytoma cells via a specific action on Rho proteins. Ann N Y Acad Sci 939:63–73.
3. Abbracchio MP, Rainaldi G, Giammarioli AM, Ceruti S, Brambilla R, Cattabeni F, Barbieri D, Franceschi C, Jacobson KA, and Malorni W (1997) The A3 adenosine receptor mediates cell spreading, reorganization of actin cytoskeleton, and distribution of Bcl-XL: studies in human astroglioma cells. Biochem Biophys Res Commun 241:297–304.
4. Aghaei M, Panjehpour M, Karami-Tehrani F, and Salami S (2011) Molecular mechanisms of A3 adenosine receptor-induced G1 cell cycle arrest and apoptosis in androgen-dependent and independent prostate cancer cell lines: involvement of intrinsic pathway. J Cancer Res Clin Oncol 137:1511–1523.
5. Ali H, Cunha-Melo JR, Saul WF, and Beaven MA (1990) Activation of phospholipase C via adenosine receptors provides synergistic signals for secretion in antigenstimulated RBL-2H3 cells. Evidence for a novel adenosine receptor. J Biol Chem 265:745–753.
6. Ansari HR, Nadeem A, Tilley SL, and Mustafa SJ (2007) Involvement of COX-1 in A3 adenosine receptor-mediated contraction through endothelium in mice aorta. Am J Physiol Heart Circ Physiol 293:H3448–H3455.
7. Antonioli L, Blandizzi C, Pacher P, and Haskó G (2013) Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Cancer 13:842–857.
8. Antonioli L, Fornai M, Colucci R, Ghisu N, Tuccori M, Awwad O, Bin A, Zoppellaro C, Castagliuolo I, and Gaion RM, et al. (2010) Control of enteric neuromuscular functions by purinergic A(3) receptors in normal rat distal colon and experimental bowel inflammation. Br J Pharmacol 161:856–871.
9. Atkinson MR, Townsend-Nicholson A, Nicholl JK, Sutherland GR, and Schofield PR (1997) Cloning, characterisation and chromosomal assignment of the human adenosine A3 receptor (ADORA3) gene. Neurosci Res 29:73–79.
10. Auchampach JA, Ge Z-D, Wan TC, Moore J, and Gross GJ (2003) A3 adenosine receptor agonist IB-MECA reduces myocardial ischemia-reperfusion injury in dogs. Am J Physiol Heart Circ Physiol 285:H607–H613.
11. Auchampach JA, Rizvi A, Qiu Y, Tang XL, Maldonado C, Teschner S, and Bolli R (1997) Selective activation of A3 adenosine receptors with N6-(3-iodobenzyl)adenosine- 59-N-methyluronamide protects against myocardial stunning and infarction without hemodynamic changes in conscious rabbits. Circ Res 80:800–809.
12. Avni I, Garzozi HJ, Barequet IS, Segev F, Varssano D, Sartani G, Chetrit N, Bakshi E, Zadok D, and Tomkins O, et al. (2010) Treatment of dry eye syndrome with orally administered CF101: data from a phase 2 clinical trial. Ophthalmology 117: 1287–1293.
13. Baraldi PG, Cacciari B, Moro S, Spalluto G, Pastorin G, Da Ros T, Klotz KN, Varani K, Gessi S, and Borea PA (2002) Synthesis, biological activity, and molecular modeling investigation of new pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as human A(3) adenosine receptor antagonists. J Med Chem 45: 770–780.
14. Baraldi PG, Cacciari B, Romagnoli R, Spalluto G, Klotz KN, Leung E, Varani K, Gessi S, Merighi S, and Borea PA (1999) Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c] pyrimidine derivatives as highly potent and selective human A(3) adenosine receptor antagonists. J Med Chem 42:4473–4478.
15. Baraldi PG, Cacciari B, Romagnoli R, Spalluto G, Moro S, Klotz K-N, Leung E, Varani K, Gessi S, and Merighi S, et al. (2000) Pyrazolo[4,3-e]1,2,4-triazolo[1,5-c] pyrimidine derivatives as highly potent and selective human A(3) adenosine receptor antagonists: influence of the chain at the N(8) pyrazole nitrogen. J Med Chem 43:4768–4780.
16. Baraldi PG, Fruttarolo F, Tabrizi MA, Preti D, Romagnoli R, El-Kashef H, Moorman A, Varani K, Gessi S, and Merighi S, et al. (2003) Design, synthesis, and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c] pyrimidines as new A2A and A3 adenosine receptors antagonists. JMed Chem46: 1229–1241.
17. Baraldi PG, Preti D, Borea PA, and Varani K (2012) Medicinal chemistry of A₃ adenosine receptor modulators: pharmacological activities and therapeutic implications. J Med Chem 55:5676–5703.
18. Barbieri D, Abbracchio MP, Salvioli S, Monti D, Cossarizza A, Ceruti S, Brambilla R, Cattabeni F, Jacobson KA, and Franceschi C (1998) Apoptosis by 2-chloro-29-deoxyadenosine and 2-chloro-adenosine in human peripheral blood mononuclear cells. Neurochem Int 32:493–504.
19. Barnholt KE, Kota RS, Aung HH, and Rutledge JC (2009) Adenosine blocks IFNg- induced phosphorylation of STAT1 on serine 727 to reduce macrophage activation. J Immunol 183:6767–6777.
20. Bar-Yehuda S, Luger D, Ochaion A, Cohen S, Patokaa R, Zozulya G, Silver PB, de Morales JM, Caspi RR, and Fishman P (2011) Inhibition of experimental autoimmune uveitis by the A3 adenosine receptor agonist CF101. Int J Mol Med 28: 727–731.
21. Bar-Yehuda S, Madi L, Barak D, Mittelman M, Ardon E, Ochaion A, Cohn S, and Fishman P (2002) Agonists to the A3 adenosine receptor induce G-CSF production via NF-kappaB activation: a new class of myeloprotective agents. Exp Hematol 30:1390–1398.
22. Bar-Yehuda S, Rath-Wolfson L, Del Valle L, Ochaion A, Cohen S, Patoka R, Zozulya G, Barer F, Atar E, and Piña-Oviedo S, et al. (2009) Induction of an antiinflammatory effect and prevention of cartilage damage in rat knee osteoarthritis by CF101 treatment. Arthritis Rheum 60:3061–3071.
23. Bar-Yehuda S, Silverman MH, Kerns WD, Ochaion A, Cohen S, and Fishman P (2007) The anti-inflammatory effect of A3 adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis. Expert Opin Investig Drugs 16: 1601–1613.
24. Bar-Yehuda S, Stemmer SM, Madi L, Castel D, Ochaion A, Cohen S, Barer F, Zabutti A, Perez-Liz G, and Del Valle L, et al. (2008) The A3 adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the Wnt and NF-kappaB signal transduction pathways. Int J Oncol 33:287–295.
25. Björklund O, Halldner-Henriksson L, Yang J, Eriksson TM, Jacobson MA, Daré E, and Fredholm BB (2008a) Decreased behavioral activation following caffeine, amphetamine and darkness in A3 adenosine receptor knock-out mice. Physiol Behav 95:668–676.
26. Björklund O, Shang M, Tonazzini I, Daré E, and Fredholm BB (2008b) Adenosine A1 and A3 receptors protect astrocytes from hypoxic damage. Eur J Pharmacol 596: 6–13.
27. Blay J, White TD, and Hoskin DW (1997) The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res 57:2602– 2605.
28. Blaisdell FW (2002) The pathophysiology of skeletal muscle ischemia and the reperfusion syndrome: a review. Cardiovasc Surg 10:620–630.
29. Boison D (2007) Adenosine as a modulator of brain activity. Drug News Perspect 20: 607–611.
30. Boison D (2008) The adenosine kinase hypothesis of epileptogenesis. Prog Neurobiol 84:249–262.
31. Borea PA, Dalpiaz A, Varani K, Gilli P, and Gilli G (2000) Can thermodynamic measurements of receptor binding yield information on drug affinity and efficacy? Biochem Pharmacol 60:1549–1556.
32. Bouma MG, Jeunhomme TM, Boyle DL, Dentener MA, Voitenok NN, van den Wildenberg FAJM, and Buurman WA (1997) Adenosine inhibits neutrophil degranulation in activated human whole blood: involvement of adenosine A2 and A3 receptors. J Immunol 158:5400–5408.
33. Brand A, Vissiennon Z, Eschke D, and Nieber K (2001) Adenosine A(1) and A(3) receptors mediate inhibition of synaptic transmission in rat cortical neurons. Neuropharmacology 40:85–95.
34. Brandon CI, Vandenplas M, Dookwah H, and Murray TF (2006) Cloning and pharmacological characterization of the equine adenosine A3 receptor. J Vet Pharmacol Ther 29:255–263.
35. Broussas M, Cornillet-Lefèbvre P, Potron G, and Nguyen P (1999) Inhibition of fMLP-triggered respiratory burst of human monocytes by adenosine: involvement of A3 adenosine receptor. J Leukoc Biol 66:495–501.
36. Broussas M, Cornillet-Lefèbvre P, Potron G, and Nguyên P (2002) Adenosine inhibits tissue factor expression by LPS-stimulated human monocytes: involvement of the A3 adenosine receptor. Thromb Haemost 88:123–130.
37. Burnett LA, Blais EM, Unadkat JD, Hille B, Tilley SL, and Babcock DF (2010) Testicular expression of Adora3i2 in Adora3 knockout mice reveals a role of mouse A3Ri2 and human A3Ri3 adenosine receptors in sperm. J Biol Chem 285: 33662–33670.
38. Burnstock G, Brouns I, Adriaensen D, and Timmermans JP (2012) Purinergic signaling in the airways. Pharmacol Rev 64:834–868.
39. Burnstock G, Fredholm BB, and Verkhratsky A (2011) Adenosine and ATP receptors in the brain. Curr Top Med Chem 11:973–1011.
40. Burnstock G and Ralevic V (2014) Purinergic signaling and blood vessels in health and disease. Pharmacol Rev 66:102–192.
41. Butler JJ, Mader JS, Watson CL, Zhang H, Blay J, and Hoskin DW (2003) Adenosine inhibits activation-induced T cell expression of CD2 and CD28 co-stimulatory molecules: role of interleukin-2 and cyclic AMP signaling pathways. J Cell Biochem 89:975–91.
42. Butler M, Sanmugalingam D, Burton VJ, Wilson T, Pearson R, Watson RP, Smith P, and Parkinson SJ (2012) Impairment of adenosine A3 receptor activity disrupts neutrophil migratory capacity and impacts innate immune function in vivo. Eur J Immunol 42:3358–3368.
43. Calzetta L, Spina D, Cazzola M, Page CP, Facciolo F, Rendina EA, and Matera MG (2011) Pharmacological characterization of adenosine receptors on isolated human bronchi. Am J Respir Cell Mol Biol 45:1222–1231.
44. Can-fite Biopharma Ltd. (2010) A3 adenosine receptor allosteric modulators. US0144156.
45. Carruthers AM and Fozard JR (1993) Adenosine A3 receptors: two into one won’t go. Trends Pharmacol Sci 14:290–291.
46. Chanyshev B, Shainberg A, Isak A, Litinsky A, Chepurko Y, Tosh DK, Phan K, Gao ZG, Hochhauser E, and Jacobson KA (2012) Anti-ischemic effects of multivalent dendrimeric A₃ adenosine receptor agonists in cultured cardiomyocytes and in the isolated rat heart. Pharmacol Res 65:338–346.
47. Chen Y, Corriden R, Inoue Y, Yip L, Hashiguchi N, Zinkernagel A, Nizet V, Insel PA, and Junger WG (2006) ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors. Science 314:1792–1795.
48. Chen Z, Janes K, Chen C, Doyle T, Bryant L, Tosh DK, Jacobson KA, and Salvemini D (2012) Controlling murine and rat chronic pain through A3 adenosine receptor activation. FASEB J 26:1855–1865.
49. Choi IY, Lee JC, Ju C, Hwang S, Cho GS, Lee HW, Choi WJ, Jeong LS, and Kim WK (2011) A3 adenosine receptor agonist reduces brain ischemic injury and inhibits inflammatory cell migration in rats. Am J Pathol 179:2042–2052.
50. Christofi FL, Zhang H, Yu JG, Guzman J, Xue J, Kim M, Wang Y-Z, and Cooke HJ (2001) Differential gene expression of adenosine A1, A2a, A2b, and A3 receptors in the human enteric nervous system. J Comp Neurol 439:46–64.
51. Chung KY, Rasmussen SGF, Liu T, Li S, DeVree BT, Chae PS, Calinski D, Kobilka BK, Woods VL Jr, and Sunahara RK (2011) Conformational changes in the G protein Gs induced by the b2 adrenergic receptor. Nature 477:611–615.
52. Cinalli AR, Guarracino JF, Fernandez V, Roquel LI, and Losavio AS (2013) Inosine induces presynaptic inhibition of acetylcholine release by activation of A3 adenosine receptors at the mouse neuromuscular junction. Br J Pharmacol 169:1810–1823.
53. Cohen S, Stemmer SM, Zozulya G, Ochaion A, Patoka R, Barer F, Bar-Yehuda S, Rath-Wolfson L, Jacobson KA, and Fishman P (2011) CF102 an A3 adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver. J Cell Physiol 226:2438–2447.
54. Corriden R, Self T, Akong-Moore K, Nizet V, Kellam B, Briddon SJ, and Hill SJ (2013) Adenosine-A3 receptors in neutrophil microdomains promote the formation of bacteria-tethering cytonemes. EMBO Rep 14:726–732.
55. Cross HR, Murphy E, Black RG, Auchampach J, and Steenbergen C (2002) Overexpression of A(3) adenosine receptors decreases heart rate, preserves energetics, and protects ischemic hearts. Am J Physiol Heart Circ Physiol 283:H1562–H1568.
56. da Rocha Lapa F, de Oliveira AP, Accetturi BG, de Oliveira Martins I, Domingos HV, de Almeida Cabrini D, de Lima WT, and Santos AR (2013) Anti-inflammatory effects of inosine in allergic lung inflammation in mice: evidence for the participation of adenosine A2A and A 3 receptors. Purinergic Signal 9:325–336.
57. David M, Akerman L, Ziv M, Kadurina M, Gospodinov D, Pavlotsky F, Yankova R, Kouzeva V, Ramon M, and Silverman MH, et al. (2012) Treatment of plaque-type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial. J Eur Acad Dermatol Venereol 26:361–367.
58. Decking UK, Schlieper G, Kroll K, and Schrader J (1997) Hypoxia-induced inhibition of adenosine kinase potentiates cardiac adenosine release. Circ Res 81:154–164.
59. De Mattei M, Varani K, Masieri FF, Pellati A, Ongaro A, Fini M, Cadossi R, Vincenzi F, Borea PA, and Caruso A (2009) Adenosine analogs and electromagnetic fields inhibit prostaglandin E2 release in bovine synovial fibroblasts. Osteoarthritis Cartilage 17:252–262.
60. DeNinno MP, Masamune H, Chenard LK, DiRico KJ, Eller C, Etienne JB, Tickner JE, Kennedy SP, Knight DR, and Kong J, et al. (2003) 39-Aminoadenosine-59-uronamides: discovery of the first highly selective agonist at the human adenosine A3 receptor. J Med Chem 46:353–355.
61. Dennis SH, Jaafari N, Cimarosti H, Hanley JG, Henley JM, and Mellor JR (2011) Oxygen/glucose deprivation induces a reduction in synaptic AMPA receptors on hippocampal CA3 neurons mediated by mGluR1 and adenosine A3 receptors. J Neurosci 31:11941–11952.
62. Diaz RJ, Hinek A, and Wilson GJ (2010) Direct evidence of chloride ion efflux in ischaemic and pharmacological preconditioning of cultured cardiomyocytes. Cardiovasc Res 87:545–551.
63. Dickenson JM, Reeder S, Rees B, Alexander S, and Kendall D (2003) Functional expression of adenosine A2A and A3 receptors in the mouse dendritic cell line XS-106. Eur J Pharmacol 474:43–51.
64. Di Tullio MA, Tayebati SK, and Amenta F (2004) Identification of adenosine A1 and A3 receptor subtypes in rat pial and intracerebral arteries. Neurosci Lett 366: 48–52.
65. Dixon AK, Gubitz AK, Sirinathsinghji DJS, Richardson PJ, and Freeman TC (1996) Tissue distribution of adenosine receptor mRNAs in the rat. Br J Pharmacol 118: 1461–1468.
66. Drabczyńska A, Schumacher B, Müller CE, Karolak-Wojciechowska J, Michalak B, Pekala E, and Kieć-Kononowicz K (2003) Impact of the aryl substituent kind and distance from pyrimido[2,1-f]purindiones on the adenosine receptor selectivity and antagonistic properties. Eur J Med Chem 38:397–402.
67. Du L, Gao ZG, Nithipatikom K, Ijzerman AP, Veldhoven JP, Jacobson KA, Gross GJ, and Auchampach JA (2012) Protection from myocardial ischemia/reperfusion injury by a positive allosteric modulator of the A₃ adenosine receptor. J Pharmacol Exp Ther 340:210–217.
68. Dunwiddie TV, Diao L, Kim HO, Jiang J-L, and Jacobson KA (1997) Activation of hippocampal adenosine A3 receptors produces a desensitization of A1 receptormediated responses in rat hippocampus. J Neurosci 17:607–614.
69. El-Awady MS, Ansari HR, Fil D, Tilley SL, and Mustafa SJ (2011) NADPH oxidase pathway is involved in aortic contraction induced by A3 adenosine receptor in mice. J Pharmacol Exp Ther 338:711–717.
70. el-Hashim A, D’Agostino B, Matera MG, and Page C (1996) Characterization of adenosine receptors involved in adenosine-induced bronchoconstriction in allergic rabbits. Br J Pharmacol 119:1262–1268.
71. Englert M, Quitterer U, and Klotz KN (2002) Effector coupling of stably transfected human A3 adenosine receptors in CHO cells. Biochem Pharmacol 64:61–65.
72. Fedorova IM, Jacobson MA, Basile A, and Jacobson KA (2003) Behavioral characterization of mice lacking the A3 adenosine receptor: sensitivity to hypoxic neurodegeneration. Cell Mol Neurobiol 23:431–447.
73. Feoktistov I and Biaggioni I (1995) Adenosine A2b receptors evoke interleukin-8 secretion in human mast cells. An enprofylline-sensitive mechanism with implications for asthma. J Clin Invest 96:1979–1986.
74. Feoktistov I, Ryzhov S, Goldstein AE, and Biaggioni I (2003) Mast cell-mediated stimulation of angiogenesis: cooperative interaction between A2B and A3 adenosine receptors. Circ Res 92:485–492.
75. Fernandez P, Jara C, Aguilera V, Caviedes L, Diaz F, Radojkovic C, Veas C, Lamperti L, Escudero C, and Aguayo C (2012) Adenosine A₂A and A₃ receptors are involved in the human endothelial progenitor cells migration. J Cardiovasc Pharmacol 59: 397–404.
76. Fini M, Pagani S, Giavaresi G, De Mattei M, Ongaro A, Varani K, Vincenzi F, Massari L, and Cadossi M (2013) Functional tissue engineering in articular cartilage repair: is there a role for electromagnetic biophysical stimulation? Tissue Eng Part B Rev 19:353–367.
77. Fishman P, Bar-Yehuda S, Ardon E, Rath-Wolfson L, Barrer F, Ochaion A, and Madi L (2003) Targeting the A3 adenosine receptor for cancer therapy: inhibition of prostate carcinoma cell growth by A3AR agonist. Anticancer Res 23 (3A): 2077–2083.
78. Fishman P, Bar-Yehuda S, Barer F, Madi L, Multani AS, and Pathak S (2001) The A3 adenosine receptor as a new target for cancer therapy and chemoprotection. Exp Cell Res 269:230–236.
79. Fishman P, Bar-Yehuda S, Liang BT, and Jacobson KA (2012) Pharmacological and therapeutic effects of A3 adenosine receptor agonists. Drug Discov Today 17: 359–366.
80. Fishman P, Bar-Yehuda S, Madi L, and Cohn I (2002a) A3 adenosine receptor as a target for cancer therapy. Anticancer Drugs 13:437–443.
81. Fishman P, Bar-Yehuda S, Madi L, Rath-Wolfson L, Ochaion A, Cohen S, and Baharav E (2006) The PI3K-NF-kappaB signal transduction pathway is involved in mediating the anti-inflammatory effect of IB-MECA in adjuvant-induced arthritis. Arthritis Res Ther 8:R169.
82. Fishman P, Bar-Yehuda S, Ohana G, Barer F, Ochaion A, Erlanger A, and Madi L (2004) An agonist to the A3 adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3 beta and NF-kappa B. Oncogene 23:2465–2471.
83. Fishman P, Bar-Yehuda S, Ohana G, Pathak S, Wasserman L, Barer F, and Multani AS (2000) Adenosine acts as an inhibitor of lymphoma cell growth: a major role for the A3 adenosine receptor. Eur J Cancer 36:1452–1458.
84. Fishman P, Bar-Yehuda S, Synowitz M, Powell JD, Klotz KN, Gessi S, and Borea PA (2009) Adenosine receptors and cancer. Handbook Exp Pharmacol 193:399–441.
85. Fishman P, Bar-Yehuda S, and Vagman L (1998) Adenosine and other low molecular weight factors released by muscle cells inhibit tumor cell growth. Cancer Res 58: 3181–3187.
86. Fishman P, Cohen S, and Bar-Yehuda S (2013) Targeting the A3 adenosine receptor for glaucoma treatment (review). Mol Med Rep 7:1723–1725.
87. Fishman P, Madi L, Bar-Yehuda S, Barer F, Del Valle L, and Khalili K (2002b) Evidence for involvement of Wnt signaling pathway in IB-MECA mediated suppression of melanoma cells. Oncogene 21:4060–4064.
88. Flögel U, Burghoff S, van Lent PL, Temme S, Galbarz L, Ding Z, El-Tayeb A, Huels S, Bönner F, and Borg N, et al. (2012) Selective activation of adenosine A2A receptors on immune cells by a CD73-dependent prodrug suppresses joint inflammation in experimental rheumatoid arthritis. Sci Transl Med 4:146ra108.
89. Forrest CM, Harman G, McMillan RB, Stoy N, Stone TW, and Darlington LG (2005) Modulation of cytokine release by purine receptors in patients with rheumatoid arthritis. Clin Exp Rheumatol 23:89–92.
90. Forte G, Sorrentino R, Montinaro A, Pinto A, and Morello S (2011) Cl-IB-MECA enhances TNF-a release in peritoneal macrophages stimulated with LPS. Cytokine 54:161–166.
91. Fossetta J, Jackson J, Deno G, Fan X, Du XK, Bober L, Soudé-Bermejo A, de Bouteiller O, Caux C, and Lunn C, et al. (2003) Pharmacological analysis of calcium responses mediated by the human A3 adenosine receptor in monocyte-derived dendritic cells and recombinant cells. Mol Pharmacol 63:342–350.
92. Fotheringham JA, Mayne MB, Grant JA, and Geiger JD (2004) Activation of adenosine receptors inhibits tumor necrosis factor-alpha release by decreasing TNFalpha mRNA stability and p38 activity. Eur J Pharmacol 497:87–95.
93. Fozard JR and Carruthers AM (1993) Adenosine A3 receptors mediate hypotension in the angiotensin II-supported circulation of the pithed rat. Br J Pharmacol 109:3–5.
94. Fozard JR, Pfannkuche H-J, and Schuurman H-J (1996) Mast cell degranulation following adenosine A3 receptor activation in rats. Eur J Pharmacol 298:293–297.
95. Fozard JR (2010) From Hypertension (+) to Asthma: Interactions with the Adenosine A3 Receptor from a Personal Perspective, in A3 Adenosine Receptors from Cell Biology to Pharmacology and Therapeutics (Borea PA, ed) pp 3–26, Springer, New York.
96. Fredholm BB (2014) Adenosine—a physiological or pathophysiological agent? J Mol Med (Berl) 92:201–206.
97. Fredholm BB, IJzerman AP, Jacobson KA, Klotz K-N, and Linden J (2001) International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 53:527–552.
98. Fredholm BB, IJzerman AP, Jacobson KA, Linden J, and Müller CE (2011) International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors—an update. Pharmacol Rev 63:1–34.
99. Gallo-Rodriguez C, Ji XD, Melman N, Siegman BD, Sanders LH, Orlina J, Fischer B, Pu Q, Olah ME, and van Galen PJ, et al. (1994) Structure-activity relationships of N6-benzyladenosine-59-uronamides as A3-selective adenosine agonists. J Med Chem 37:636–646.
100. Gao ZG, Chen A, Barak D, Kim SK, Müller CE, and Jacobson KA (2002) Identification by site-directed mutagenesis of residues involved in ligand recognition and activation of the human A3 adenosine receptor. J Biol Chem 277:19056–19063.
101. Gao ZG and Jacobson KA (2007) Emerging adenosine receptor agonists. Expert Opin Emerg Drugs 12:479–492.
102. Gao Z, Li BS, Day YJ, and Linden J (2001) A3 adenosine receptor activation triggers phosphorylation of protein kinase B and protects rat basophilic leukemia 2H3 mast cells from apoptosis. Mol Pharmacol 59:76–82.
103. Gao ZG, Verzijl D, Zweemer A, Ye K, Göblyös A, Ijzerman AP, and Jacobson KA (2011) Functionally biased modulation of A(3) adenosine receptor agonist efficacy and potency by imidazoquinolinamine allosteric enhancers. Biochem Pharmacol 82:658–668.
104. Garcia N, Priego M, Hurtado E, Obis T, Santafe MM, Tomàs M, Lanuza MA, and Tomàs J (2014) Adenosine A2B and A3 receptor location at the mouse neuromuscular junction. J Anat 225:109–17.
105. Gatta F, Del Giudice MR, Borioni A, Borea PA, Dionisotti S, and Ongini E (1993) Synthesis of imidazo[1,2-c]pyrazolo[4,3-e]pyrimidines, pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines and 1,2,4-triazolo[5,1-i]purines: new potent adenosine A2 receptor antagonists. Eur J Med Chem 28:569–576.
106. Gazoni LM, Walters DM, Unger EB, Linden J, Kron IL, and Laubach VE (2010) Activation of A1, A2A, or A3 adenosine receptors attenuates lung ischemiareperfusion injury. J Thorac Cardiovasc Surg 140:440–446.
107. Ge ZD, Peart JN, Kreckler LM, Wan TC, Jacobson MA, Gross GJ, and Auchampach JA (2006) Cl-IB-MECA [2-chloro-N6-(3-iodobenzyl)adenosine-59-N-methylcarboxamide] reduces ischemia/reperfusion injury in mice by activating the A3 adenosine receptor. J Pharmacol Exp Ther 319:1200–1210.
108. Ge ZD, van der Hoeven D, Maas JE, Wan TC, and Auchampach JA (2010) A(3) adenosine receptor activation during reperfusion reduces infarct size through actions on bone marrow-derived cells. J Mol Cell Cardiol 49:280–286.
109. Germack R and Dickenson JM (2005) Adenosine triggers preconditioning through MEK/ERK1/2 signalling pathway during hypoxia/reoxygenation in neonatal rat cardiomyocytes. J Mol Cell Cardiol 39:429–442.
110. Germack R and Dickenson JM (2004) Characterization of ERK1/2 signalling pathways induced by adenosine receptor subtypes in newborn rat cardiomyocytes. Br J Pharmacol 141:329–339.
111. Germack R, Griffin M, and Dickenson JM (2004) Activation of protein kinase B by adenosine A1 and A3 receptors in newborn rat cardiomyocytes. J Mol Cell Cardiol 37:989–999.
112. Gessi S, Cattabriga E, Avitabile A, Gafa’ R, Lanza G, Cavazzini L, Bianchi N, Gambari R, Feo C, and Liboni A, et al. (2004a) Elevated expression of A3 adenosine receptors in human colorectal cancer is reflected in peripheral blood cells. Clin Cancer Res 10:5895–5901.
113. Gessi S, Fogli E, Sacchetto V, Merighi S, Varani K, Preti D, Leung E, Maclennan S, and Borea PA (2010a) Adenosine modulates HIF-1alpha, VEGF, IL-8, and foam cell formation in a human model of hypoxic foam cells. Arterioscler Thromb Vasc Biol 30:90–97.
114. Gessi S, Fogli E, Sacchetto V, Varani K, Merighi S, Leung E, Lennan SM, and Borea PA (2008a) Thermodynamics of A2B adenosine receptor binding discriminates agonistic from antagonistic behaviour. Biochem Pharmacol 75:562–569.
115. Gessi S, Merighi S, Fazzi D, Stefanelli A, Varani K, and Borea PA (2011a) Adenosine receptor targeting in health and disease. Expert Opin Investig Drugs 20: 1591–1609.
116. Gessi S, Merighi S, Sacchetto V, Simioni C, and Borea PA (2011b) Adenosine receptors and cancer. Biochim Biophys Acta 1808:1400–1412.
117. Gessi S, Merighi S, Stefanelli A, Fazzi D, Varani K, and Borea PA (2013) A(1) and A(3) adenosine receptors inhibit LPS-induced hypoxia-inducible factor-1 accumulation in murine astrocytes. Pharmacol Res 76:157–170.
118. Gessi S, Merighi S, Stefanelli A, Mirandola P, Bonfatti A, Fini S, Sensi A, Marci R, Varani K, and Borea PA, et al. (2012) Downregulation of A(1) and A(2B) adenosine receptors in human trisomy 21 mesenchymal cells from first-trimester chorionic villi. Biochim Biophys Acta 1822:1660–1670.
119. Gessi S, Merighi S, Varani K, Cattabriga E, Benini A, Mirandola P, Leung E, Mac Lennan S, Feo C, and Baraldi S, et al. (2007) Adenosine receptors in colon carcinoma tissues and colon tumoral cell lines: focus on the A(3) adenosine subtype. J Cell Physiol 211:826–836.
120. Gessi S, Merighi S, Varani K, Leung E, Mac Lennan S, and Borea PA (2008b) The A3 adenosine receptor: an enigmatic player in cell biology. Pharmacol Ther 117: 123–140.
121. Gessi S, Sacchetto V, Fogli E, and Fozard J (2009) A3 adenosine receptor regulation of cells of the immune system and modulation of inflammation, in A3 Adenosine Receptors from Cell Biology to Pharmacology and Therapeutics (Borea PA ed) pp 235–256, Springer, New York.
122. Gessi S, Sacchetto V, Fogli E, Merighi S, Varani K, Baraldi PG, Tabrizi MA, Leung E, Maclennan S, and Borea PA (2010b) Modulation of metalloproteinase-9 in U87MG glioblastoma cells by A3 adenosine receptors. Biochem Pharmacol 79:1483–1495.
123. Gessi S, Varani K, Merighi S, Cattabriga E, Avitabile A, Gavioli R, Fortini C, Leung E, Mac Lennan S, and Borea PA (2004b) Expression of A3 adenosine receptors in human lymphocytes: up-regulation in T cell activation. Mol Pharmacol 65: 711–719.
124. Gessi S, Varani K, Merighi S, Cattabriga E, Iannotta V, Leung E, Baraldi PG, and Borea PA (2002) A(3) adenosine receptors in human neutrophils and promyelocytic HL60 cells: a pharmacological and biochemical study. Mol Pharmacol 61:415–424.
125. Gessi S, Varani K, Merighi S, Morelli A, Ferrari D, Leung E, Baraldi PG, Spalluto G, and Borea PA (2001) Pharmacological and biochemical characterization of A3 adenosine receptors in Jurkat T cells. Br J Pharmacol 134:116–126.
126. Goblyos A, Brussee J, Ijzerman AP, Gao ZJ, and Jacobson K (2009), inventors, Government of the USA, assignee. A3 adenosine receptor allosteric modulators. US patent 20090054476 A1. 26 Feb 2009.
127. Gomez G, Zhao W, and Schwartz LB (2011) Disparity in Fc«RI-induced degranulation of primary human lung and skin mast cells exposed to adenosine. J Clin Immunol 31:479–487.
128. González-Fernández E, Sánchez-Gómez MV, Pérez-Samartín A, Arellano RO, and Matute C (2014) A3 Adenosine receptors mediate oligodendrocyte death and ischemic damage to optic nerve. Glia 62:199–216.
129. Grandoch M, Hoffmann J, Röck K, Wenzel F, Oberhuber A, Schelzig H, and Fischer JW (2013) Novel effects of adenosine receptors on pericellular hyaluronan matrix: implications for human smooth muscle cell phenotype and interactions with monocytes during atherosclerosis. Basic Res Cardiol 108:340.
130. Hammarberg C, Fredholm BB, and Schulte G (2004) Adenosine A3 receptor-mediated regulation of p38 and extracellular-regulated kinase ERK1/2 via phosphatidylinositol-39-kinase. Biochem Pharmacol 67:129–134.
131. Hammarberg C, Schulte G, and Fredholm BB (2003) Evidence for functional adenosine A3 receptors in microglia cells. J Neurochem 86:1051–1054.
132. Hannon JP, Pfannkuche HJ, and Fozard JR (1995) A role for mast cells in adenosine A3 receptor-mediated hypotension in the rat. Br J Pharmacol 115:945–952.
133. Harish A, Hohana G, Fishman P, Arnon O, and Bar-Yehuda S (2003) A3 adenosine receptor agonist potentiates natural killer cell activity. Int J Oncol 23:1245–1249.
134. Harrison GJ, Cerniway RJ, Peart J, Berr SS, Ashton K, Regan S, Paul Matherne G, and Headrick JP (2002) Effects of A(3) adenosine receptor activation and gene knock-out in ischemic-reperfused mouse heart. Cardiovasc Res 53:147–155.
135. Haskó G and Cronstein BN (2004) Adenosine: an endogenous regulator of innate immunity. Trends Immunol 25:33–39.
136. Haskó G and Cronstein B (2013) Regulation of inflammation by adenosine. Front Immunol 4:85.
137. Haskó G, Linden J, Cronstein B, and Pacher P (2008) Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 7: 759–770.
138. Haskó G, Németh ZH, Vizi ES, Salzman AL, and Szabó C (1998) An agonist of adenosine A3 receptors decreases interleukin-12 and interferon-gamma production and prevents lethality in endotoxemic mice. Eur J Pharmacol 358:261–268.
139. Haskó G, Pacher P, Vizi ES, and Illes P (2005) Adenosine receptor signaling in the brain immune system. Trends Pharmacol Sci 26:511–516.
140. Haskó G, Szabó C, Németh ZH, Kvetan V, Pastores SM, and Vizi ES (1996) Adenosine receptor agonists differentially regulate IL-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. J Immunol 157: 4634–4640.
141. Headrick JP and Peart J (2005) A3 adenosine receptor-mediated protection of the ischemic heart. Vascul Pharmacol 42:271–279.
142. Heitman LH, Göblyös A, Zweemer AM, Bakker R, Mulder-Krieger T, van Veldhoven JPD, de Vries H, Brussee J, and Ijzerman AP (2009) A series of 2,4-disubstituted quinolines as a new class of allosteric enhancers of the adenosine A3 receptor. J Med Chem 52:926–931.
143. Hill SJ, May LT, Kellam B, and Woolard J (2014) Allosteric interactions at adenosine A(1) and A(3) receptors: new insights into the role of small molecules and receptor dimerization. Br J Pharmacol 171:1102–1113.
144. Hinze AV, Mayer P, Harst A, and von Kügelgen I (2012) Adenosine A(3) receptorinduced proliferation of primary human coronary smooth muscle cells involving the induction of early growth response genes. J Mol Cell Cardiol 53:639–645.
145. Hochhauser E, Leshem D, Kaminski O, Cheporko Y, Vidne BA, and Shainberg A (2007) The protective effect of prior ischemia reperfusion adenosine A1 or A3 receptor activation in the normal and hypertrophied heart. Interact Cardiovasc Thorac Surg 6:363–368.
146. Hofer S, Ivarsson L, Stoitzner P, Auffinger M, Rainer C, Romani N, and Heufler C (2003) Adenosine slows migration of dendritic cells but does not affect other aspects of dendritic cell maturation. J Invest Dermatol 121:300–307.
147. Hofer M, Dušek L, Hoferová Z, Stixová L, and Pospíšil M (2011) Expression of mRNA for adenosine A(1), A(2a), A(2b), and A(3) receptors in HL-60 cells: dependence on cell cycle phases. Physiol Res 60:913–920.
148. Hoskin DW, Butler JJ, Drapeau D, Haeryfar SM, and Blay J (2002) Adenosine acts through an A3 receptor to prevent the induction of murine anti-CD3-activated killer T cells. Int J Cancer 99:386–395.
149. Hoskin DW, Mader JS, Furlong SJ, Conrad DM, and Blay J (2008) Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review). Int J Oncol 32:527–535.
150. Hoskin DW, Reynolds T, and Blay J (1994a) Adenosine as a possible inhibitor of killer T-cell activation in the microenvironment of solid tumours. Int J Cancer 59: 854–855.
151. Hoskin DW, Reynolds T, and Blay J (1994b) 2-Chloroadenosine inhibits the MHCunrestricted cytolytic activity of anti-CD3-activated killer cells: evidence for the involvement of a non-A1/A2 cell-surface adenosine receptor. Cell Immunol 159: 85–93.
152. Hu H, Lu W, Zhang M, Zhang X, Argall AJ, Patel S, Lee GE, Kim YC, Jacobson KA, and Laties AM, et al. (2010) Stimulation of the P2X7 receptor kills rat retinal ganglion cells in vivo. Exp Eye Res 91:425–432.
153. Hua X, Chason KD, Fredholm BB, Deshpande DA, Penn RB, and Tilley SL (2008) Adenosine induces airway hyperresponsiveness through activation of A3 receptors on mast cells. J Allergy Clin Immunol 122:107–113, e1–e7.
154. Hussain A, Gharanei AM, Nagra AS, and Maddock HL (2014) Caspase inhibition via A3 adenosine receptors: a new cardioprotective mechanism against myocardial infarction. Cardiovasc Drugs Ther 28:19–32.
155. Jacobson KA (1998) Adenosine A3 receptors: novel ligands and paradoxical effects. Trends Pharmacol Sci 19:184–191.
156. Jacobson KA (2010) GPCR ligand-dendrimer (GLiDe) conjugates: future smart drugs? Trends Pharmacol Sci 31:575–579.
157. Jacobson KA, Klutz AM, Tosh DK, Ivanov AA, Preti D, and Baraldi PG (2009) Medicinal chemistry of the A3 adenosine receptor: agonists, antagonists, and receptor engineering. Handb Exp Pharmacol 193:1232159.
158. Jacobson KA and Melman A (2010), inventors. Methanocarba adenosine derivatives and dendrimer conjugated thereof. Patent 20120264769. 2 Dec 2010.
159. Jacobson KA, Nikodijević O, Shi D, Gallo-Rodriguez C, Olah ME, Stiles GL, and Daly JW (1993) A role for central A3-adenosine receptors. Mediation of behavioral depressant effects. FEBS Lett 336:57–60.
160. Jacobson KA, Park KS, Jiang J-L, Kim YC, Olah ME, Stiles GL, and Ji X-D (1997) Pharmacological characterization of novel A3 adenosine receptor-selective antagonists. Neuropharmacology 36:1157–1165.
161. Jacobson KA, Siddiqi SM, Olah ME, Ji XD, Melman N, Bellamkonda K, Meshulam Y, Stiles GL, and Kim HO (1995) Structure-activity relationships of 9-alkyladenine and ribose-modified adenosine derivatives at rat A3 adenosine receptors. J Med Chem 38:1720–1735.
162. Jajoo S, Mukherjea D, Watabe K, and Ramkumar V (2009) Adenosine A(3) receptor suppresses prostate cancer metastasis by inhibiting NADPH oxidase activity. Neoplasia 11:1132–1145.
163. Janes K, Esposito E, Doyle T, Cuzzocrea S, Tosh DK, Jacobson KA, and Salvemini D (2014a) A3 adenosine receptor agonist prevents the development of paclitaxelinduced neuropathic pain by modulating spinal glial-restricted redox-dependent signaling pathways. Pain, in press.
164. Janes K, Wahlman C, Little JW, Doyle T, Tosh DK, Jacobson KA, and Salvemini D (2014b) Spinal neuroimmmune activation is independent of T-cell infiltration and attenuated by A3 adenosine receptor agonists in a model of oxaliplatin-induced peripheral neuropathy. Brain Behav Immun, in press.
165. Jeong LS, Jin DZ, Kim HO, Shin DH, Moon HR, Gunaga P, Chun MW, Kim YC, Melman N, and Gao ZG, et al. (2003) N6-substituted D-49-thioadenosine-59-methyluronamides: potent and selective agonists at the human A3 adenosine receptor. J Med Chem 46:3775–3777.
166. Ji XD, Melman N, and Jacobson KA (1996) Interactions of flavonoids and other phytochemicals with adenosine receptors. J Med Chem 39:781–788.
167. Ji XD, von Lubitz D, Olah ME, Stiles GL, and Jacobson KA (1994) Species differences in ligand affinity at central A3-adenosine receptors. Drug Dev Res 33:51–59.
168. Jones MR, Zhao Z, Sullivan CP, Schreiber BM, Stone PJ, Toselli PA, Kagan HM, Cohen RA, and Ravid K (2004) A(3) adenosine receptor deficiency does not influence atherogenesis. J Cell Biochem 92:1034–1043.
169. Jordan JE, Thourani VH, Auchampach JA, Robinson JA, Wang NP, and Vinten-Johansen J (1999) A(3) adenosine receptor activation attenuates neutrophil function and neutrophil-mediated reperfusion injury. Am J Physiol 277:H1895–H1905.
170. Kadomatsu M, Nakajima S, Kato H, Gu L, Chi Y, Yao J, and Kitamura M (2012) Cordycepin as a sensitizer to tumour necrosis factor (TNF)-a-induced apoptosis through eukaryotic translation initiation factor 2a (eIF2a)- and mammalian target of rapamycin complex 1 (mTORC1)-mediated inhibition of nuclear factor (NF)-kB. Clin Exp Immunol 168:325–332.
171. Kamiya H, Kanno T, Fujita Y, Gotoh A, Nakano T, and Nishizaki T (2012) Apoptosisrelated gene transcription in human A549 lung cancer cells via A(3) adenosine receptor. Cell Physiol Biochem 29:687–696.
172. Kanno T, Nakano T, Fujita Y, Gotoh A, and Nishizaki T (2012) Adenosine induces apoptosis in SBC-3 human lung cancer cells through A(3) adenosine receptordependent AMID upregulation. Cell Physiol Biochem 30:666–677.
173. Kenakin TP (2009) 7TM receptor allostery: putting numbers to shapeshifting proteins. Trends Pharmacol Sci 30:460–469.
174. Kenakin TP (2012) Biased signalling and allosteric machines: new vistas and challenges for drug discovery. Br J Pharmacol 165:1659–1669.
175. Keov P, Sexton PM, and Christopoulos A (2011) Allosteric modulation of G proteincoupled receptors: a pharmacological perspective. Neuropharmacology 60:24–35.
176. Kim Y, Hechler B, Klutz AM, Gachet C, and Jacobson KA (2008a) Toward multivalent signaling across G protein-coupled receptors from poly(amidoamine) dendrimers. Bioconjug Chem 19:406–411.
177. Kim YH, Hwang HS, Kim YT, Kim HS, and Park YW (2008b) Modulation of matrix metalloproteinase secretion by adenosine A3 receptor in preeclamptic villous explants. Reprod Sci 15:939–949.
178. Kim YC, Ji XD, and Jacobson KA (1996) Derivatives of the triazoloquinazoline adenosine antagonist (CGS15943) are selective for the human A3 receptor subtype. J Med Chem 39:4142–4148.
179. Kim HO, Ji XD, Siddiqi SM, Olah ME, Stiles GL, and Jacobson KA (1994) 2-Substitution of N6-benzyladenosine-59-uronamides enhances selectivity for A3 adenosine receptors. J Med Chem 37:3614–3621.
180. Kim H, Kang JW, Lee S, Choi WJ, Jeong LS, Yang Y, Hong JT, and Yoon Y (2010) A3 adenosine receptor antagonist, truncated Thio-Cl-IB-MECA, induces apoptosis in T24 human bladder cancer cells. Anticancer Res 30:2823–2830.
181. Kim TH, Kim YK, and Woo JS (2012) The adenosine A3 receptor agonist Cl-IBMECA induces cell death through Ca²⁺/ROS-dependent down regulation of ERK and Akt in A172 human glioma cells. Neurochem Res 37:2667–2677.
182. Kim GD, Oh J, Jeong LS, and Lee SK (2013) Thio-Cl-IB-MECA, a novel A₃ adenosine receptor agonist, suppresses angiogenesis by regulating PI3K/AKT/mTOR and ERK signaling in endothelial cells. Biochem Biophys Res Commun 437:79–86.
183. Klotz KN, Falgner N, Kachler S, Lambertucci C, Vittori S, Volpini R, and Cristalli G (2007) [3H]HEMADO—a novel tritiated agonist selective for the human adenosine A3 receptor. Eur J Pharmacol 556:14–18.
184. Koda K, Salazar-Rodriguez M, Corti F, Chan NY, Estephan R, Silver RB, Mochly-Rosen D, and Levi R (2010) Aldehyde dehydrogenase activation prevents reperfusion arrhythmias by inhibiting local renin release from cardiac mast cells. Circulation 122:771–781.
185. Kohno Y, Ji X, Mawhorter SD, Koshiba M, and Jacobson KA (1996a) Activation of A3 adenosine receptors on human eosinophils elevates intracellular calcium. Blood 88: 3569–3574.
186. Kohno Y, Sei Y, Koshiba M, Kim HO, and Jacobson KA (1996b) Induction of apoptosis in HL-60 human promyelocytic leukemia cells by adenosine A(3) receptor agonists. Biochem Biophys Res Commun 219:904–910.
187. Koscsó B, Csóka B, Pacher P, and Haskó G (2011) Investigational A₃ adenosine receptor targeting agents. Expert Opin Investig Drugs 20:757–768.
188. Kreckler LM, Wan TC, Ge Z-D, and Auchampach JA (2006) Adenosine inhibits tumor necrosis factor-a release from mouse peritoneal macrophages via A2A and A2B but not the A3 adenosine receptor. J Pharmacol Exp Ther 317:172–180.
189. Kumar V (2013) Adenosine as an endogenous immunoregulator in cancer pathogenesis: where to go? Purinergic Signal 9:145–165.
190. la Sala A, Gadina M, and Kelsall BL (2005) G(i)-protein-dependent inhibition of IL-12 production is mediated by activation of the phosphatidylinositol 3-kinase-protein 3 kinase B/Akt pathway and JNK. J Immunol 175:2994–2999.
191. Lee HS, Chung HJ, Lee HW, Jeong LS, and Lee SK (2011) Suppression of inflammation response by a novel A adenosine receptor agonist thio-Cl-IB-MECA through inhibition of Akt and NF-kB signaling. Immunobiology 216:997–1003.
192. Lee JE, Bokoch G, and Liang BT (2001) A novel cardioprotective role of RhoA: new signaling mechanism for adenosine. FASEB J 15:1886–1894.
193. Lee JY, Jhun BS, Oh YT, Lee JH, Choe W, Baik HH, Ha J, Yoon KS, Kim SS, and Kang I (2006a) Activation of adenosine A3 receptor suppresses lipopolysaccharide-induced TNF-alpha production through inhibition of PI 3-kinase/Akt and NF-kappaB activation in murine BV2 microglial cells. Neurosci Lett 396:1–6.
194. Lee HT, Kim M, Joo JD, Gallos G, Chen JF, and Emala CW (2006b) A3 adenosine receptor activation decreases mortality and renal and hepatic injury in murine septic peritonitis. Am J Physiol Regul Integr Comp Physiol 291:R959–R969.
195. Leshem-Lev D, Hochhauser E, Chanyshev B, Isak A, and Shainberg A (2010) Adenosine A1 and A3 receptor agonists reduce hypoxic injury through the involvement of P38 MAPK. Mol Cell Biochem 345: 153–160.
196. Leung CT, Li A, Banerjee J, Gao ZG, Kambayashi T, Jacobson KA, and Civan MM (2014) The role of activated adenosine receptors in degranulation of human LAD2 mast cells. Purinergic Signal 10:465–475.
197. Li AH, Moro S, Melman N, Ji XD, and Jacobson KA (1998) Structure-activity relationships and molecular modeling of 3, 5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists. J Med Chem 41:3186–3201.
198. Liang BT, Urso M, Zambraski E, and Jacobson KA (2010) Adenosine A3 receptors in muscle protection, in A3 Adenosine Receptors from Cell Biology to Pharmacology and Therapeutics (Borea PA, ed) pp 257–280, Springer, New York.
199. Linden J (1994) Cloned adenosine A3 receptors: pharmacological properties, species differences and receptor functions. Trends Pharmacol Sci 15:298–306.
200. Linden J, Taylor HE, Robeva AS, Tucker AL, Stehle JH, Rivkees SA, Fink JS, and Reppert SM (1993) Molecular cloning and functional expression of a sheep A3 adenosine receptor with widespread tissue distribution. Mol Pharmacol 44: 524–532.
201. Liu Y, Ytrehus K, and Downey JM (1994) Evidence that translocation of protein kinase C is a key event during ischemic preconditioning of rabbit myocardium. J Mol Cell Cardiol 26:661–668.
202. Lopes LV, Rebola N, Pinheiro PC, Richardson PJ, Oliveira CR, and Cunha RA (2003) Adenosine A3 receptors are located in neurons of the rat hippocampus. Neuroreport 14:1645–1648.
203. Lu J, Pierron A, and Ravid K (2003) An adenosine analogue, IB-MECA, downregulates estrogen receptor alpha and suppresses human breast cancer cell proliferation. Cancer Res 63:6413–6423.
204. Mabley J, Soriano F, Pacher P, Haskó G, Marton A, Wallace R, Salzman A, and Szabó C (2003) The adenosine A3 receptor agonist, N6-(3-iodobenzyl)-adenosine-59-Nmethyluronamide, is protective in two murine models of colitis. Eur J Pharmacol 466:323–329.
205. Macek TA, Schaffhauser H, and Conn PJ (1998) Protein kinase C and A3 adenosine receptor activation inhibit presynaptic metabotropic glutamate receptor (mGluR) function and uncouple mGluRs from GTP-binding proteins. J Neurosci 18: 6138–6146.
206. Maconi A, Pastorin G, Da Ros T, Spalluto G, Gao ZG, Jacobson KA, Baraldi PG, Cacciari B, Varani K, and Moro S, et al. (2002) Synthesis, biological properties, and molecular modeling investigation of the first potent, selective, and water-soluble human A(3) adenosine receptor antagonist. J Med Chem 45:3579–3582.
207. Maddock HL, Mocanu MM, and Yellon DM (2002) Adenosine A(3) receptor activation protects the myocardium from reperfusion/reoxygenation injury. Am J Physiol Heart Circ Physiol 283:H1307–H1313.
208. Madi L, Bar-Yehuda S, Barer F, Ardon E, Ochaion A, and Fishman P (2003) A3 adenosine receptor activation in melanoma cells: association between receptor fate and tumor growth inhibition. J Biol Chem 278:42121–42130.
209. Madi L, Cohen S, Ochayin A, Bar-Yehuda S, Barer F, and Fishman P (2007) Overexpression of A3 adenosine receptor in peripheral blood mononuclear cells in rheumatoid arthritis: involvement of nuclear factor-kappaB in mediating receptor level. J Rheumatol 34:20–26.
210. Madi L, Ochaion A, Rath-Wolfson L, Bar-Yehuda S, Erlanger A, Ohana G, Harish A, Merimski O, Barer F, and Fishman P (2004) The A3 adenosine receptor is highly expressed in tumor versus normal cells: potential target for tumor growth inhibition. Clin Cancer Res 10:4472–4479.
211. Madi L, Rosenberg-Haggen B, Nyska A, and Korenstein R (2013) Enhancing pigmentation via activation of A3 adenosine receptors in B16 melanoma cells and in human skin explants. Exp Dermatol 22:74–77.
212. Martin L, Pingle SC, Hallam DM, Rybak LP, and Ramkumar V (2006) Activation of the adenosine A3 receptor in RAW 264.7 cells inhibits lipopolysaccharidestimulated tumor necrosis factor-alpha release by reducing calcium-dependent activation of nuclear factor-kappaB and extracellular signal-regulated kinase 1/2. J Pharmacol Exp Ther 316:71–78.
213. Matot I, Weiniger CF, Zeira E, Galun E, Joshi BV, and Jacobson KA (2006) A3 adenosine receptors and mitogen-activated protein kinases in lung injury following in vivo reperfusion. Crit Care 10:R65.
214. McIntosh VJ and Lasley RD (2012) Adenosine receptor-mediated cardioprotection: are all 4 subtypes required or redundant? J Cardiovasc Pharmacol Ther 17:21–33.
215. McWhinney CD, Dudley MW, Bowlin TL, Peet NP, Schook L, Bradshaw M, De M, Borcherding DR, and Edwards CK 3rd (1996) Activation of adenosine A3 receptors on macrophages inhibits tumor necrosis factor-a. Eur J Pharmacol 310:209–216. Melillo G (2004) HIF-1: a target for cancer, ischemia and inflammation—too good to be true? Cell Cycle 3:154–155.
216. Melman A, Gao ZG, Kumar D, Wan TC, Gizewski E, Auchampach JA, and Jacobson KA (2008) Design of (N)-methanocarba adenosine 59-uronamides as speciesindependent A3 receptor-selective agonists. Bioorg Med Chem Lett 18:2813–2819.
217. Menjoge AR, Kannan RM, and Tomalia DA (2010) Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications. Drug Discov Today 15:171–185.
218. Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Leung E, MacLennan S, Baraldi PG, and Borea PA (2005a) A3 adenosine receptors modulate hypoxiainducible factor-1alpha expression in human A375 melanoma cells. Neoplasia 7: 894–903.
219. Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Leung E, Maclennan S, Baraldi PG, and Borea PA (2007a) Hypoxia inhibits paclitaxel-induced apoptosis through adenosine-mediated phosphorylation of bad in glioblastoma cells. Mol Pharmacol 72:162–172.
220. Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Leung E, Maclennan S, and Borea PA (2005b) A3 adenosine receptor activation inhibits cell proliferation via phosphatidylinositol 3-kinase/Akt-dependent inhibition of the extracellular signal-regulated kinase 1/2 phosphorylation in A375 human melanoma cells. J Biol Chem 280:19516–19526.
221. Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Leung E, Maclennan S, and Borea PA (2006) Adenosine modulates vascular endothelial growth factor expression via hypoxia-inducible factor-1 in human glioblastoma cells. Biochem Pharmacol 72:19–31.
222. Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Simioni C, Leung E, Maclennan S, Baraldi PG, and Borea PA (2007b) Caffeine inhibits adenosine-induced accumulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and interleukin-8 expression in hypoxic human colon cancer cells. Mol Pharmacol 72:395–406.
223. Merighi S, Mirandola P, Milani D, Varani K, Gessi S, Klotz KN, Leung E, Baraldi PG, and Borea PA (2002a) Adenosine receptors as mediators of both cell proliferation and cell death of cultured human melanoma cells. J Invest Dermatol 119:923–933.
224. Merighi S, Mirandola P, Varani K, Gessi S, Leung E, Baraldi PG, Tabrizi MA, and Borea PA (2003) A glance at adenosine receptors: novel target for antitumor therapy. Pharmacol Ther 100:31–48.
225. Merighi S, Simioni C, Gessi S, Varani K, Mirandola P, Tabrizi MA, Baraldi PG, and Borea PA (2009) A(2B) and A(3) adenosine receptors modulate vascular endothelial growth factor and interleukin-8 expression in human melanoma cells treated with etoposide and doxorubicin. Neoplasia 11:1064–1073.
226. Merighi S, Simioni C, Lane R, and IJzerman AP (2010) Regulation of second messenger systems and intracellular pathways, in A3 Adenosine Receptors from Cell Biology to Pharmacology and Therapeutics (Borea PA, ed) pp 257–280, Springer, New York.
227. Merighi S, Varani K, Gessi S, Cattabriga E, Iannotta V, Ulouglu C, Leung E, and Borea PA (2001) Pharmacological and biochemical characterization of adenosine receptors in the human malignant melanoma A375 cell line. Br J Pharmacol 134:1215–1226.
228. Merighi S, Varani K, Gessi S, Klotz K-N, Leung E, Baraldi PG, and Borea PA (2002b) Binding thermodynamics at the human A(3) adenosine receptor. Biochem Pharmacol 63:157–161.
229. Meyerhof W, Müller-Brechlin R, and Richter D (1991) Molecular cloning of a novel putative G-protein coupled receptor expressed during rat spermiogenesis. FEBS Lett 284:155–160.
230. Mitchell CH, Peterson-Yantorno K, Carré DA, McGlinn AM, Coca-Prados M, Stone RA, and Civan MM (1999) A3 adenosine receptors regulate Cl- channels of nonpigmented ciliary epithelial cells. Am J Physiol 276:C659–C666.
231. Montinaro A, Forte G, Sorrentino R, Luciano A, Palma G, Arra C, Adcock IM, Pinto A, and Morello S (2012) Adoptive immunotherapy with Cl-IB-MECA-treated CD8+ T cells reduces melanoma growth in mice. PLoS ONE 7:e45401.
232. Morello S, Sorrentino R, Porta A, Forte G, Popolo A, Petrella A, and Pinto A (2009) Cl-IB-MECA enhances TRAIL-induced apoptosis via the modulation of NF-kappaB signalling pathway in thyroid cancer cells. J Cell Physiol 221:378–386.
233. Morschl E, Molina JG, Volmer JB, Mohsenin A, Pero RS, Hong JS, Kheradmand F, Lee JJ, and Blackburn MR (2008) A3 adenosine receptor signaling influences pulmonary inflammation and fibrosis. Am J Respir Cell Mol Biol 39:697–705.
234. Mozzicato S, Joshi BV, Jacobson KA, and Liang BT (2004) Role of direct RhoAphospholipase D1 interaction in mediating adenosine-induced protection from cardiac ischemia. FASEB J 18:406–408.
235. Müller CE, Thorand M, Qurishi R, Diekmann M, Jacobson KA, Padgett WL, and Daly JW (2002) Imidazo[2,1-i]purin-5-ones and related tricyclic water-soluble purine derivatives: potent A(2A)- and A(3)-adenosine receptor antagonists. J Med Chem 45: 3440–3450.
236. Mulloy DP, Sharma AK, Fernandez LG, Zhao Y, Lau CL, Kron IL, and Laubach VE (2013) Adenosine A3 receptor activation attenuates lung ischemia-reperfusion injury. Ann Thorac Surg 95:1762–1767.
237. Murrison EM, Goodson SJ, Edbrooke MR, and Harris CA (1996) Cloning and characterisation of the human adenosine A3 receptor gene. FEBS Lett 384:243–246.
238. Nagaya H, Gotoh A, Kanno T, and Nishizaki T (2013) A3 adenosine receptor mediates apoptosis in in vitro RCC4-VHL human renal cancer cells by up-regulating AMID expression. J Urol 189:321–328.
239. Nakamura K, Yoshikawa N, Yamaguchi Y, Kagota S, Shinozuka K, and Kunitomo M (2006) Antitumor effect of cordycepin (39-deoxyadenosine) on mouse melanoma and lung carcinoma cells involves adenosine A3 receptor stimulation. Anticancer Res 26 (1A):43–47.
240. Nayak A, Chandra G, Hwang I, Kim K, Hou X, Kim HO, Sahu PK, Roy KK, Yoo J, and Lee Y, et al. (2014) Synthesis and anti-renal fibrosis activity of conformationally locked truncated 2-hexynyl-N(6)-substituted-(N)-methanocarba-nucleosides as A3 adenosine receptor antagonists and partial agonists. J Med Chem 57: 1344–1354.
241. Neary JT, McCarthy M, Kang Y, and Zuniga S (1998) Mitogenic signaling from P1 and P2 purinergic receptors to mitogen-activated protein kinase in human fetal astrocyte cultures. Neurosci Lett 242:159–162.
242. Nishat S, Shabir H, Azmi AS, and Ansari HR (2012) A(3) adenosine receptor: a plausible therapeutic target for cardio-protection in diabetes. Recent Patents Cardiovasc Drug Discov 7:59–70.
243. Nogi Y, Kanno T, Nakano T, Fujita Y, Tabata C, Fukuoka K, Gotoh A, and Nishizaki T (2012) AMP converted from intracellularly transported adenosine upregulates p53 expression to induce malignant pleural mesothelioma cell apoptosis. Cell Physiol Biochem 30:61–74.
244. Ochaion A, Bar-Yehuda S, Cohen S, Amital H, Jacobson KA, Joshi BV, Gao ZG, Barer F, Patoka R, and Del Valle L, et al. (2008) The A3 adenosine receptor agonist CF502 inhibits the PI3K, PKB/Akt and NF-kappaB signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant-induced arthritis rats. Biochem Pharmacol 76:482–494.
245. Ochaion A, Bar-Yehuda S, Cohen S, Barer F, Patoka R, Amital H, Reitblat T, Reitblat A, Ophir J, and Konfino I, et al. (2009) The anti-inflammatory target A(3) adenosine receptor is over-expressed in rheumatoid arthritis, psoriasis and Crohn’s disease. Cell Immunol 258:115–122.
246. Ohsawa K, Sanagi T, Nakamura Y, Suzuki E, Inoue K, and Kohsaka S (2012) Adenosine A3 receptor is involved in ADP-induced microglial process extension and migration. J Neurochem 121:217–227.
247. Okamura T, Kurogi Y, Nishikawa H, Hashimoto K, Fujiwara H, and Nagao Y (2002) 1,2,4-Triazolo[5,1-i]purine derivatives as highly potent and selective human adenosine A(3) receptor ligands. J Med Chem 45:3703–3708.
248. Olah ME, Gallo-Rodriguez C, Jacobson KA, and Stiles GL (1994) [125I]AB-MECA, a high affinity radioligand for the rat A3 adenosine receptor. Mol Pharmacol 45: 978–982.
249. Ongaro A, Varani K, Masieri FF, Pellati A, Massari L, Cadossi R, Vincenzi F, Borea PA, Fini M, and Caruso A, et al. (2012) Electromagnetic fields (EMFs) and adenosine receptors modulate prostaglandin E(2) and cytokine release in human osteoarthritic synovial fibroblasts. J Cell Physiol 227:2461–2469.
250. Otsuki T, Kanno T, Fujita Y, Tabata C, Fukuoka K, Nakano T, Gotoh A, and Nishizaki T (2012) A3 adenosine receptor-mediated p53-dependent apoptosis in Lu-65 human lung cancer cells. Cell Physiol Biochem 30:210–220.
251. Ozola V, Thorand M, Diekmann M, Qurishi R, Schumacher B, Jacobson KA, and Müller CE (2003) 2-Phenylimidazo[2,1-i]purin-5-ones: structure-activity relationships and characterization of potent and selective inverse agonists at Human A3 adenosine receptors. Bioorg Med Chem 11:347–356.
252. Palmer TM, Benovic JL, and Stiles GL (1995) Agonist-dependent phosphorylation and desensitization of the rat A3 adenosine receptor. Evidence for a G-proteincoupled receptor kinase-mediated mechanism. J Biol Chem 270:29607–29613.
253. Palmer TM and Stiles GL (2000) Identification of threonine residues controlling the agonist-dependent phosphorylation and desensitization of the rat A(3) adenosine receptor. Mol Pharmacol 57:539–545.
254. Panjehpour M and Karami-Tehrani F (2004) An adenosine analog (IB-MECA) inhibits anchorage-dependent cell growth of various human breast cancer cell lines. Int J Biochem Cell Biol 36:1502–1509.
255. Panther E, IdzkoM, Herouy Y, Rheinen H, Gebicke-Haerter PJ, Mrowietz U, Dichmann S, and Norgauer J (2001) Expression and function of adenosine receptors in human dendritic cells. FASEB J 15:1963–1970.
256. Paoletta S, Tosh DK, Finley A, Gizewski ET, Moss SM, Gao ZG, Auchampach JA, Salvemini D, and Jacobson KA (2013) Rational design of sulfonated A3 adenosine receptor-selective nucleosides as pharmacological tools to study chronic neuropathic pain. J Med Chem 56:5949–5963.
257. Peart JN and Headrick JP (2007) Adenosinergic cardioprotection: multiple receptors, multiple pathways. Pharmacol Ther 114:208–221.
258. Pugliese AM, Coppi E, Volpini R, Cristalli G, Corradetti R, Jeong LS, Jacobson KA, and Pedata F (2007) Role of adenosine A3 receptors on CA1 hippocampal neurotransmission during oxygen-glucose deprivation episodes of different duration. Biochem Pharmacol 74:768–779.
259. Pugliese AM, Latini S, Corradetti R, and Pedata F (2003) Brief, repeated, oxygen-glucose deprivation episodes protect neurotransmission from a longer ischemic episode in the in vitro hippocampus: role of adenosine receptors. Br J Pharmacol 140:305–314.
260. Ralevic V and Burnstock G (1998) Receptors for purines and pyrimidines. Pharmacol Rev 50:413–492.
261. Ramkumar V, Stiles GL, Beaven MA, and Ali H (1993) The A3 adenosine receptor is the unique adenosine receptor which facilitates release of allergic mediators in mast cells. J Biol Chem 268:16887–16890.
262. Raskovalova T, Huang X, Sitkovsky M, Zacharia LC, Jackson EK, and Gorelik E (2005) Gs protein-coupled adenosine receptor signaling and lytic function of activated NK cells. J Immunol 175:4383–4391.
263. Rasmussen SG, DeVree BT, Zou Y, Kruse AC, Chung KY, Kobilka TS, Thian FS, Chae PS, Pardon E, and Calinski D, et al. (2011) Crystal structure of the b2 adrenergic receptor-Gs protein complex. Nature 477:549–555.
264. Rath-Wolfson L, Bar-Yehuda S, Madi L, Ochaion A, Cohen S, Zabutti A, and Fishman P (2006) IB-MECA, an A3 adenosine receptor agonist prevents bone resorption in rats with adjuvant induced arthritis. Clin Exp Rheumatol 24:400–406.
265. Rebola N, Rodrigues RJ, Oliveira CR, and Cunha RA (2005) Different roles of adenosine A1, A2A and A3 receptors in controlling kainate-induced toxicity in cortical cultured neurons. Neurochem Int 47:317–325.
266. Reeves JJ, Harris CA, Hayes BP, Butchers PR, and Sheehan MJ (2000) Studies on the effects of adenosine A3 receptor stimulation on human eosinophils isolated from non-asthmatic or asthmatic donors. Inflamm Res 49:666–672.
267. Reeves JJ, Jones CA, Sheehan MJ, Vardey CJ, and Whelan CJ (1997) Adenosine A3 receptors promote degranulation of rat mast cells both in vitro and in vivo. Inflamm Res 46:180–184.
268. Reiss AB and Cronstein BN (2012) Regulation of foam cells by adenosine. Arterioscler Thromb Vasc Biol 32:879–886.
269. Ren T, Grants I, Alhaj M, McKiernan M, Jacobson M, Hassanain HH, Frankel W, Wunderlich J, and Christofi FL (2011) Impact of disrupting adenosine A₃ receptors (A₃⁻/⁻AR) on colonic motility or progression of colitis in the mouse. Inflamm Bowel Dis 17:1698–1713.
270. Reshkin SJ, Guerra L, Bagorda A, Debellis L, Cardone R, Li AH, Jacobson KA, and Casavola V (2000) Activation of A(3) adenosine receptor induces calcium entry and chloride secretion in A(6) cells. J Membr Biol 178:103–113.
271. Ribeiro JA and Sebastião AM (1984) Enhancement of tetrodotoxin-induced axonal blockade by adenosine, adenosine analogues, dibutyryl cyclic AMP and methylxanthines in the frog sciatic nerve. Br J Pharmacol 83:485–492.
272. Ribeiro JA and Sebastião AM (1986) Adenosine receptors and calcium: basis for proposing a third (A3) adenosine receptor. Prog Neurobiol 26:179–209.
273. Rivera-Oliver M and Díaz-Ríos M (2014) Using caffeine and other adenosine receptor antagonists and agonists as therapeutic tools against neurodegenerative diseases: a review. Life Sci 101:1–9.
274. Rivkees SA (1994) Localization and characterization of adenosine receptor expression in rat testis. Endocrinology 135:2307–2313.
275. Rivkees SA, Thevananther S, and Hao H (2000) Are A3 adenosine receptors expressed in the brain? Neuroreport 11:1025–1030.
276. Roseti C, Palma E, Martinello K, Fucile S, Morace R, Esposito V, Cantore G, Arcella A, Giangaspero F, and Aronica E, et al. (2009) Blockage of A2A and A3 adenosine receptors decreases the desensitization of human GABA(A) receptors microtransplanted to Xenopus oocytes. Proc Natl Acad Sci USA 106:15927–15931.
277. Ryzhov S, Goldstein AE, Matafonov A, Zeng D, Biaggioni I, and Feoktistov I (2004) Adenosine-activated mast cells induce IgE synthesis by B lymphocytes: an A2B-mediated process involving Th2 cytokines IL-4 and IL-13 with implications for asthma. J Immunol 172:7726–7733.
278. Sajjadi FG, Takabayashi K, Foster AC, Domingo RC, and Firestein GS (1996) Inhibition of TNF-a expression by adenosine: role of A3 adenosine receptors. J Immunol 156:3435–3442.
279. Saki M, Tsumuki H, Nonaka H, Shimada J, and Ichimura M (2002) KF26777 (2-(4-bromophenyl)-7,8-dihydro-4-propyl-1H-imidazo[2,1-i]purin-5(4H)-one dihydrochloride), a new potent and selective adenosine A3 receptor antagonist. Eur J Pharmacol 444: 133–141.
280. Sakowicz-Burkiewicz M, Kitowska A, Grden M, Maciejewska I, Szutowicz A, and Pawelczyk T (2013) Differential effect of adenosine receptors on growth of human colon cancer HCT 116 and HT-29 cell lines. Arch Biochem Biophys 533:47–54.
281. Salie R, Moolman JA, and Lochner A (2012) The mechanism of beta-adrenergic preconditioning: roles for adenosine and ROS during triggering and mediation. Basic Res Cardiol 107:281.
282. Salvatore CA, Jacobson MA, Taylor HE, Linden J, and Johnson RG (1993) Molecular cloning and characterization of the human A3 adenosine receptor. Proc Natl Acad Sci USA 90:10365–10369.
283. Salvatore CA, Tilley SL, Latour AM, Fletcher DS, Koller BH, and Jacobson MA (2000) Disruption of the A(3) adenosine receptor gene in mice and its effect on stimulated inflammatory cells. J Biol Chem 275:4429–4434.
284. Sandhu H, Cooper S, Eckert M, Pisula L, Chinweike C, Gharanei M, and Maddock HL (2014) Cardioprotection during chemotherapy: a case study to understand intracellular mechanisms to combat the cardiotoxicity of sunitinib. Heart 100:A7–A8.
285. Sattin A and Rall TW (1970) The effect of adenosine and adenine nucleotides on the cyclic adenosine 39, 59-phosphate content of guinea pig cerebral cortex slices. Mol Pharmacol 6:13–23.
286. Sawynok J, Zarrindast MR, Reid AR, and Doak GJ (1997) Adenosine A3 receptor activation produces nociceptive behaviour and edema by release of histamine and 5-hydroxytryptamine. Eur J Pharmacol 333:1–7.
287. Schlötzer-Schrehardt U, Zenkel M, Decking U, Haubs D, Kruse FE, Jünemann A, Coca-Prados M, and Naumann GO (2005) Selective upregulation of the A3 adenosine receptor in eyes with pseudoexfoliation syndrome and glaucoma. Invest Ophthalmol Vis Sci 46:2023–2034.
288. Schulte G and Fredholm BB (2000) Human adenosine A(1), A(2A), A(2B), and A(3) receptors expressed in Chinese hamster ovary cells all mediate the phosphorylation of extracellular-regulated kinase 1/2. Mol Pharmacol 58:477–482.
289. Schulte G and Fredholm BB (2002) Signaling pathway from the human adenosine A (3) receptor expressed in Chinese hamster ovary cells to the extracellular signalregulated kinase 1/2. Mol Pharmacol 62:1137–1146.
290. Sebastiao AM, Ribeiro FF, and Ribeiro JA (2012) From A1 to A3 en passant through A (2A) receptors in the hippocampus: pharmacological implications. CNS Neurol Disord Drug Targets 11:652–663.
291. Sei Y, Von Lubitz DKJE, Abbracchio MP, Ji X-D, and Jacobson KA (1997) Adenosine A3 receptor agonist-induced neurotoxicity in rat cerebellar granule neurons. Drug Dev Res 40:267–273.
292. Shepherd RK, Linden J, and Duling BR (1996) Adenosine-induced vasoconstriction in vivo. Role of the mast cell and A3 adenosine receptor. Circ Res 78:627–634.
293. Shneyvays V, Leshem D, Zinman T, Mamedova LK, Jacobson KA, and Shainberg A (2005) Role of adenosine A1 and A3 receptors in regulation of cardiomyocyte homeostasis after mitochondrial respiratory chain injury. Am J Physiol Heart Circ Physiol 288:H2792–H2801.
294. Shneyvays V, Mamedova L, Zinman T, Jacobson K, and Shainberg A (2001) Activation of A(3)adenosine receptor protects against doxorubicin-induced cardiotoxicity. J Mol Cell Cardiol 33:1249–1261.
295. Shneyvays V, Nawrath H, Jacobson KA, and Shainberg A (1998) Induction of apoptosis in cardiac myocytes by an A3 adenosine receptor agonist. Exp Cell Res 243: 383–397.
296. Shneyvays V, Zinman T, and Shainberg A (2004) Analysis of calcium responses mediated by the A3 adenosine receptor in cultured newborn rat cardiac myocytes. Cell Calcium 36:387–396.
297. Siddiqi SM, Jacobson KA, Esker JL, Olah ME, Ji XD, Melman N, Tiwari KN, Secrist JA 3rd, Schneller SW, and Cristalli G, et al. (1995) Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors. J Med Chem 38:1174–1188.
298. Silverman MH, Strand V, Markovits D, Nahir M, Reitblat T, Molad Y, Rosner I, Rozenbaum M, Mader R, and Adawi M, et al. (2008) Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial. J Rheumatol 35:41–48.
299. Smith SR, Denhardt G, and Terminelli C (2002) A role for histamine in cytokine modulation by the adenosine A(3) receptor agonist, 2-Cl-IB-MECA. Eur J Pharmacol 457:57–69.
300. Soares AS, Costa VM, Diniz C, and Fresco P (2014) Combination of Cl‑IB‑MECA with paclitaxel is a highly effective cytotoxic therapy causing mTOR‑dependent autophagy and mitotic catastrophe on human melanoma cells. J Cancer Res Clin Oncol 140:921–935.
301. Spicuzza L, Di Maria G, and Polosa R (2006) Adenosine in the airways: implications and applications. Eur J Pharmacol 533:77–88.
302. Stamp LK, Hazlett J, Roberts RL, Frampton C, Highton J, and Hessian PA (2012) Adenosine receptor expression in rheumatoid synovium: a basis for methotrexate action. Arthritis Res Ther 14:R138.
303. Stemmer SM, Benjaminov O, Medalia G, Ciuraru NB, Silverman MH, Bar-Yehuda S, Fishman S, Harpaz Z, Farbstein M, and Cohen S, et al. (2013) CF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation study. Oncologist 18:25–26.
304. Stoddart LA, Kellam B, Briddon SJ, and Hill SJ (2014) Effect of a toggle switch mutation in TM6 of the human adenosine A₃ receptor on Gi protein-dependent signalling and Gi-independent receptor internalization. Br J Pharmacol 171: 3827–3844.
305. Suh BC, Kim TD, Lee JU, Seong JK, and Kim KT (2001) Pharmacological characterization of adenosine receptors in PGT-beta mouse pineal gland tumour cells. Br J Pharmacol 134:132–142.
306. Szabó C, Scott GS, Virág L, Egnaczyk G, Salzman AL, Shanley TP, and Haskó G (1998) Suppression of macrophage inflammatory protein (MIP)-1alpha production and collagen-induced arthritis by adenosine receptor agonists. Br J Pharmacol 125:379–387.
307. Taliani S, La Motta C, Mugnaini L, Simorini F, Salerno S, Marini AM, Da Settimo F, Cosconati S, Cosimelli B, and Greco G, et al. (2010) Novel N2-substituted pyrazolo [3,4-d]pyrimidine adenosine A3 receptor antagonists: inhibition of A3-mediated human glioblastoma cell proliferation. J Med Chem 53:3954–3963.
308. Talukder MA, Morrison RR, Jacobson MA, Jacobson KA, Ledent C, and Mustafa SJ (2002) Targeted deletion of adenosine A(3) receptors augments adenosine-induced coronary flow in isolated mouse heart. Am J Physiol Heart Circ Physiol 282: H2183–H2189.
309. Tchilibon S, Joshi BV, Kim SK, Duong HT, Gao ZG, and Jacobson KA (2005) (N)-methanocarba 2,N6-disubstituted adenine nucleosides as highly potent and selective A3 adenosine receptor agonists. J Med Chem 48:1745–1758.
310. Teng B, Fil D, Tilley SL, Ledent C, Krahn T, and Mustafa SJ (2013) Functional and RNA expression profile of adenosine receptor subtypes in mouse mesenteric arteries. J Cardiovasc Pharmacol 61:70–76.
311. Thiele A, Kronstein R, Wetzel A, Gerth A, Nieber K, and Hauschildt S (2004) Regulation of adenosine receptor subtypes during cultivation of human monocytes: role of receptors in preventing lipopolysaccharide-triggered respiratory burst. Infect Immun 72:1349–1357.
312. Thourani VH, Nakamura M, Ronson RS, Jordan JE, Zhao Z-Q, Levy JH, Szlam F, Guyton RA, and Vinten-Johansen J (1999a) Adenosine A(3)-receptor stimulation attenuates postischemic dysfunction through K(ATP) channels. Am J Physiol 277: H228–H235.
313. Thourani VH, Ronson RS, Jordan JE, Guyton RA, and Vinten-Johansen J (1999b) Adenosine A3 pretreatment before cardioplegic arrest attenuates postischemic cardiac dysfunction. Ann Thorac Surg 67:1732–1737.
314. Tilley SL, Tsai M, Williams CM, Wang ZS, Erikson CJ, Galli SJ, and Koller BH (2003) Identification of A3 receptor- and mast cell-dependent and -independent components of adenosine-mediated airway responsiveness in mice. J Immunol 171: 331–337.
315. Tilley SL, Wagoner VA, Salvatore CA, Jacobson MA, and Koller BH (2000) Adenosine and inosine increase cutaneous vasopermeability by activating A(3) receptors on mast cells. J Clin Invest 105:361–367.
316. Tosh DK, Yoo LS, Chinn M, Hong K, Kilbey SM 2nd, Barrett MO, Fricks IP, Harden TK, Gao ZG, and Jacobson KA (2010) Polyamidoamine (PAMAM) dendrimer conjugates of “clickable” agonists of the A3 adenosine receptor and coactivation of the P2Y14 receptor by a tethered nucleotide. Bioconjug Chem 21:372–384.
317. Tracey WR, Magee W, Masamune H, Kennedy SP, Knight DR, Buchholz RA, and Hill RJ (1997) Selective adenosine A3 receptor stimulation reduces ischemic myocardial injury in the rabbit heart. Cardiovasc Res 33:410–415.
318. Tracey WR, Magee W, Masamune H, Oleynek JJ, and Hill RJ (1998) Selective activation of adenosine A3 receptors with N6-(3-chlorobenzyl)-59-N-methylcarboxamidoadenosine (CB-MECA) provides cardioprotection via KATP channel activation. Cardiovasc Res 40: 138–145.
319. Trincavelli ML, Tuscano D, Marroni M, Falleni A, Gremigni V, Ceruti S, Abbracchio MP, Jacobson KA, Cattabeni F, and Martini C (2002a) A3 adenosine receptors in human astrocytoma cells: agonist-mediated desensitization, internalization, and down-regulation. Mol Pharmacol 62:1373–1384.
320. Trincavelli ML, Tuscano D, Marroni M, Klotz KN, Lucacchini A, and Martini C (2002b) Involvement of mitogen protein kinase cascade in agonist-mediated human A(3) adenosine receptor regulation. Biochim Biophys Acta 1591:55–62.
321. Tsuchida T, Kato T, Yamaga M, Ikebe K, Oniki Y, Irie H, and Takagi K (2003) The effect of perfusion with UW solution on the skeletal muscle and vascular endothelial exocrine function in rat hindlimbs. J Surg Res 110:266–271.
322. Urso ML, Wang R, Zambraski EJ, and Liang BT (2012) Adenosine A3 receptor stimulation reduces muscle injury following physical trauma and is associated with alterations in the MMP/TIMP response. J Appl Physiol (1985) 112:658–670.
323. van der Hoeven D, Wan TC, and Auchampach JA (2008) Activation of the A(3) adenosine receptor suppresses superoxide production and chemotaxis of mouse bone marrow neutrophils. Mol Pharmacol 74:685–696.
324. van der Putten C, Zuiderwijk-Sick EA, van Straalen L, de Geus ED, Boven LA, Kondova I, IJzerman AP, and Bajramovic JJ (2009) Differential expression of adenosine A3 receptors controls adenosine A2A receptor-mediated inhibition of TLR responses in microglia. J Immunol 182:7603–7612.
325. van Muijlwijk-Koezen JE, Timmerman H, van der Goot H, Menge WM, Frijtag Von Drabbe Künzel J, de Groote M, IJzerman AP, and IJzerman AP (2000) Isoquinoline and quinazoline urea analogues as antagonists for the human adenosine A(3) receptor. J Med Chem 43:2227–2238.
326. van Troostenburg AR, Clark EV, Carey WD, Warrington SJ, Kerns WD, Cohn I, Silverman MH, Bar-Yehuda S, Fong KL, and Fishman P (2004) Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men. Int J Clin Pharmacol Ther 42:534–542.
327. Varani K, Caramori G, Vincenzi F, Adcock I, Casolari P, Leung E, Maclennan S, Gessi S, Morello S, and Barnes PJ, et al. (2006) Alteration of adenosine receptors in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 173:398–406.
328. Varani K, Caramori G, Vincenzi F, Tosi A, Barczyk A, Contoli M, Casolari P, Triggiani M, Hansel T, and Leung E, et al. (2010) Oxidative/nitrosative stress selectively altered A(2B) adenosine receptors in chronic obstructive pulmonary disease. FASEB J 24:1192–1204.
329. Varani K, De Mattei M, Vincenzi F, Gessi S, Merighi S, Pellati A, Ongaro A, Caruso A, Cadossi R, and Borea PA (2008) Characterization of adenosine receptors in bovine chondrocytes and fibroblast-like synoviocytes exposed to low frequency low energy pulsed electromagnetic fields. Osteoarthritis Cartilage 16:292–304.
330. Varani K, Maniero S, Vincenzi F, Targa M, Stefanelli A, Maniscalco P, Martini F, Tognon M, and Borea PA (2011a) A receptors are overexpressed in pleura from patients with mesothelioma and reduce cell growth via Akt/nuclear factor-kB pathway. Am J Respir Crit Care Med 183:522–530.
331. Varani K, Massara A, Vincenzi F, Tosi A, Padovan M, Trotta F, and Borea PA (2009) Normalization of A2A and A3 adenosine receptor up-regulation in rheumatoid arthritis patients by treatment with anti-tumor necrosis factor alpha but not methotrexate. Arthritis Rheum 60:2880–2891.
332. Varani K, Merighi S, Gessi S, Klotz KN, Leung E, Baraldi PG, Cacciari B, Romagnoli R, Spalluto G, and Borea PA (2000) [(3)H]MRE 3008F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A(3) adenosine receptors. Mol Pharmacol 57:968–975.
333. Varani K, Padovan M, Govoni M, Vincenzi F, Trotta F, and Borea PA (2010a) The role of adenosine receptors in rheumatoid arthritis. Autoimmun Rev 10:61–64.
334. Varani K, Padovan M, Vincenzi F, Targa M, Trotta F, Govoni M, and Borea PA (2011b) A2A and A3 adenosine receptor expression in rheumatoid arthritis: upregulation, inverse correlation with disease activity score and suppression of inflammatory cytokine and metalloproteinase release. Arthritis Res Ther 13:R197.
335. Varani K, Vincenzi F, Tosi A, Gessi S, Casetta I, Granieri G, Fazio P, Leung E, MacLennan S, and Granieri E, et al. (2010b) A2A adenosine receptor overexpression and functionality, as well as TNF-alpha levels, correlate with motor symptoms in Parkinson’s disease. FASEB J 24:587–598.
336. Varani K, Vincenzi F, Tosi A, Targa M, Masieri FF, Ongaro A, De Mattei M, Massari L, and Borea PA (2010c) Expression and functional role of adenosine receptors in regulating inflammatory responses in human synoviocytes. Br J Pharmacol 160: 101–115.
337. Varani K, Vincenzi F, Targa M, Paradiso B, Parrilli A, Fini M, Lanza G, and Borea PA (2013) The stimulation of A(3) adenosine receptors reduces bone-residing breast cancer in a rat preclinical model. Eur J Cancer 49:482–491.
338. Velot E, Haas B, Léonard F, Ernens I, Rolland-Turner M, Schwartz C, Longrois D, Devaux Y, and Wagner DR (2008) Activation of the adenosine-A3 receptor stimulates matrix metalloproteinase-9 secretion by macrophages. Cardiovasc Res 80: 246–254.
339. Vincenzi F, Targa M, Corciulo C, Gessi S, Merighi S, Setti S, Cadossi R, Goldring MB, Borea PA, and Varani K (2013) Pulsed electromagnetic fields increased the antiinflammatory effect of AA and A adenosine receptors in human T/C-28a2 chondrocytes and hFOB 1.19 osteoblasts. PLoS ONE 8:e65561.
340. Vincenzi F, Targa M, Corciulo C, Gessi S, Merighi S, Setti S, Cadossi R, Borea PA, and Varani K (2012) The anti-tumor effect of A3 adenosine receptors is potentiated by pulsed electromagnetic fields in cultured neural cancer cells. PLoS ONE 7: e39317.
341. Volpini R, Costanzi S, Lambertucci C, Taffi S, Vittori S, Klotz KN, and Cristalli G (2002) N(6)-alkyl-2-alkynyl derivatives of adenosine as potent and selective agonists at the human adenosine A(3) receptor and a starting point for searching A(2B) ligands. J Med Chem 45:3271–3279.
342. Volpini R, Buccioni M, Dal Ben D, Lambertucci C, Lammi C, Marucci G, Ramadori AT, Klotz KN, and Cristalli G (2009) Synthesis and biological evaluation of 2-alkynyl-N6-methyl-59-N-methylcarboxamidoadenosine derivatives as potent and highly selective agonists for the human adenosine A3 receptor. J Med Chem 52: 7897–7900.
343. von Arnim CA, Verstege E, Etrich SM, and Riepe MW (2006) Mechanisms of hypoxic tolerance in presymptomatic APP23 transgenic mice. Mech Ageing Dev 127:109–114.
344. von Lubitz DK (1999) Adenosine and cerebral ischemia: therapeutic future or death of a brave concept? Eur J Pharmacol 371:85–102.
345. Von Lubitz DKJE, Lin RCS, Popik P, Carter MF, and Jacobson KA (1994) Adenosine A3 receptor stimulation and cerebral ischemia. Eur J Pharmacol 263:59–67.
346. Von Lubitz DKJE, Simpson KL, and Lin RCS (2001) Right thing at a wrong time? Adenosine A3 receptors and cerebroprotection in stroke. Ann N Y Acad Sci 939:85–96.
347. Wadsak W, Mien LK, Shanab K, Ettlinger DE, Haeusler D, Sindelar K, Lanzenberger RR, Spreitzer H, Viernstein H, and Keppler BK, et al. (2008) Preparation and first evaluation of [(18)F]FE@SUPPY: a new PET tracer for the adenosine A(3) receptor. Nucl Med Biol 35:61–66.
348. Wan TC, Ge ZD, Tampo A, Mio Y, Bienengraeber MW, Tracey WR, Gross GJ, Kwok WM, and Auchampach JA (2008) The A3 adenosine receptor agonist CP-532,903 [N6-(2,5-dichlorobenzyl)-39-aminoadenosine-59-N-methylcarboxamide] protects against myocardial ischemia/reperfusion injury via the sarcolemmal ATP-sensitive potassium channel. J Pharmacol Exp Ther 324:234–243.
349. Wan TC, Tosh DK, Du L, Gizewski ET, Jacobson KA, and Auchampach JA (2011) Polyamidoamine (PAMAM) dendrimer conjugate specifically activates the A3 adenosine receptor to improve post-ischemic/reperfusion function in isolated mouse hearts. BMC Pharmacol 11:11.
350. Wang Z, Do CW, Avila MY, Peterson-Yantorno K, Stone RA, Gao ZG, Joshi B, Besada P, Jeong LS, and Jacobson KA, et al. (2010) Nucleoside-derived antagonists to A3 adenosine receptors lower mouse intraocular pressure and act across species. Exp Eye Res 90:146–154.
351. Wen LT and Knowles AF (2003) Extracellular ATP and adenosine induce cell apoptosis of human hepatoma Li-7A cells via the A3 adenosine receptor. Br J Pharmacol 140:1009–1018.
352. Wittendorp MC, Boddeke HW, and Biber K (2004) Adenosine A3 receptor-induced CCL2 synthesis in cultured mouse astrocytes. Glia 46:410–418.
353. Wu WP, Hao JX, Halldner-Henriksson L, Xu XJ, Jacobson MA, Wiesenfeld-Hallin Z, and Fredholm BB (2002) Decreased inflammatory pain due to reduced carrageenaninduced inflammation in mice lacking adenosine A3 receptors. Neuroscience 114: 523–527.
354. Xu Z, Jang Y, Mueller RA, and Norfleet EA (2006) IB-MECA and cardioprotection. Cardiovasc Drug Rev 24:227–238.
355. Yaar R, Lamperti ED, Toselli PA, and Ravid K (2002) Activity of the A3 adenosine receptor gene promoter in transgenic mice: characterization of previously unidentified sites of expression. FEBS Lett 532:267–272.
356. Yang H, Avila MY, Peterson-Yantorno K, Coca-Prados M, Stone RA, Jacobson KA, and Civan MM (2005) The cross-species A3 adenosine-receptor antagonist MRS 1292 inhibits adenosine-triggered human nonpigmented ciliary epithelial cell fluid release and reduces mouse intraocular pressure. Curr Eye Res 30:747–754.
357. Yao Y, Sei Y, Abbracchio MP, Jiang JL, Kim YC, and Jacobson KA (1997) Adenosine A3 receptor agonists protect HL-60 and U-937 cells from apoptosis induced by A3 antagonists. Biochem Biophys Res Commun 232:317–322.
358. Yoon MH, Bae HB, and Choi JI (2005) Antinociception of intrathecal adenosine receptor subtype agonists in rat formalin test. Anesth Analg 101:1417–1421.
359. Young HW, Molina JG, Dimina D, Zhong H, Jacobson M, Chan LN, Chan TS, Lee JJ, and Blackburn MR (2004) A3 adenosine receptor signaling contributes to airway inflammation and mucus production in adenosine deaminase-deficient mice. J Immunol 173:1380–1389.
360. Zhai P, Sciarretta S, Galeotti J, Volpe M, and Sadoshima J (2011) Differential roles of GSK-3b during myocardial ischemia and ischemia/reperfusion. Circ Res 109: 502–511.
361. Zhang M, Budak MT, Lu W, Khurana TS, Zhang X, Laties AM, and Mitchell CH (2006a) Identification of the A3 adenosine receptor in rat retinal ganglion cells. Mol Vis 12:937–948.
362. Zhang M, Hu H, Zhang X, Lu W, Lim J, Eysteinsson T, Jacobson KA, Laties AM, and Mitchell CH (2010) The A3 adenosine receptor attenuates the calcium rise triggered by NMDA receptors in retinal ganglion cells. Neurochem Int 56:35–41.
363. Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, Bierma- Zeinstra S, Brandt KD, Croft P, and Doherty M, et al. (2008) OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 16:137–162.
364. Zhang X, Zhang M, Laties AM, and Mitchell CH (2006b) Balance of purines may determine life or death of retinal ganglion cells as A3 adenosine receptors prevent loss following P2X7 receptor stimulation. J Neurochem 98:566–575.
365. Zhao TC and Kukreja RC (2002) Late preconditioning elicited by activation of adenosine A(3) receptor in heart: role of NF- kappa B, iNOS and mitochondrial K (ATP) channel. J Mol Cell Cardiol 34:263–277.
366. Zhao TC and Kukreja RC (2003) Protein kinase C-delta mediates adenosine A3 receptor-induced delayed cardioprotection in mouse. Am J Physiol Heart Circ Physiol 285:H434–H441.
367. Zheng J, Wang R, Zambraski E, Wu D, Jacobson KA, and Liang BT (2007) Protective roles of adenosine A1, A2A, and A3 receptors in skeletal muscle ischemia and reperfusion injury. Am J Physiol Heart Circ Physiol 293:H3685–H3691.
368. Zhong H, Shlykov SG, Molina JG, Sanborn BM, Jacobson MA, Tilley SL, and Blackburn MR (2003) Activation of murine lung mast cells by the adenosine A3 receptor. J Immunol 171:338–345.
369. Zhou R, Chen F, Li Q, Hu DY, and Liu LM (2010) Stimulation of the adenosine A3 receptor reverses vascular hyporeactivity after hemorrhagic shock in rats. Acta Pharmacol Sin 31:413–420.
370. Zhou QY, Li C, Olah ME, Johnson RA, Stiles GL, and Civelli O (1992) Molecular cloning and characterization of an adenosine receptor: the A3 adenosine receptor. Proc Natl Acad Sci USA 89:7432–7436.
371. Zhu CB, Lindler KM, Campbell NG, Sutcliffe JS, Hewlett WA, and Blakely RD (2011) Colocalization and regulated physical association of presynaptic serotonin transporters with A₃ adenosine receptors. Mol Pharmacol 80:458–465.
372. Zhu CB, Steiner JA, Munn JL, Daws LC, Hewlett WA, and Blakely RD (2007) Rapid stimulation of presynaptic serotonin transport by A(3) adenosine receptors. J Pharmacol Exp Ther 322:332–340.
373. Zimmermann H (2000) Extracellular metabolism of ATP and other nucleotides. Naunyn Schmiedebergs Arch Pharmacol 362:299–309.